Shares of Bright Minds Biosciences Inc. (DRUG) have gained 3.9% over the past four weeks to close the last trading session at $44.68, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$81 indicates a potential upside of 81.3%.The mean estimate comprises five short-term price targets with a standard deviation of $8.34. While the lowest estimate of$72.00 indicates a 61.2% increase ...